特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
192758

過活動膀胱:パイプライン製品の分析

Overactive Bladder - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 134 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
過活動膀胱:パイプライン製品の分析
出版日: 2020年10月30日
発行: Global Markets Direct
ページ情報: 英文 134 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

過活動膀胱とは、膀胱の蓄積機能に問題が生じ、急に尿意を感じるようになるという疾患です。この場合、尿意を抑えるのは難しく、結果として不随意の排尿(失禁)に至る場合もあります。この他の症状には、一晩に2~3回は尿意を覚えて起床するというのもあります。主な治療法として、生活習慣の改善や、薬物治療による膀胱活動の緩和・失禁の防止などが挙げられます。

当レポートでは、世界各国での過活動膀胱治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

過活動膀胱の概要

治療薬の開発

  • 過活動膀胱向けパイプライン製品:概要
  • 各企業で開発中の過活動膀胱治療薬
  • 大学/研究機関で研究中の過活動膀胱治療薬
  • 過活動膀胱治療薬:開発中の製品の一覧(企業別)
  • 過活動膀胱治療薬:研究中の製品の一覧(大学/研究機関別)

過活動膀胱:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

過活動膀胱治療薬の開発に従事している企業

  • Addex Therapeutics Ltd
  • Allergan Plc
  • 旭化成ファーマ
  • アステラス製薬
  • Dompe Farmaceutici SpA
  • Dong-A ST Co., Ltd.
  • FemmePharma Global Healthcare Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hydra Biosciences Inc
  • Ion Channel Innovations LLC
  • Ipsen SA
  • Jeil Pharmaceutical Co Ltd
  • Juniper Pharmaceuticals Inc
  • キッセイ薬品工業
  • キョーリン製薬
  • Lipella Pharmaceuticals Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • 小野薬品工業
  • Recordati SpA
  • Roivant Sciences Ltd
  • Sanofi
  • Seoul Pharma Co Ltd
  • Taris Biomedical LLC
  • TheraVida Inc
  • 東レ
  • XuanZhu Pharma Co Ltd

薬剤のプロファイル

過活動膀胱治療薬:開発が休止状態の製品

過活動膀胱治療薬:開発が中止された製品

過活動膀胱関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

List of Tables

  • Number of Products under Development for Overactive Bladder, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Overactive Bladder - Pipeline by Aetas Pharma Co Ltd, H2 2020
  • Overactive Bladder - Pipeline by Allergan Ltd, H2 2020
  • Overactive Bladder - Pipeline by Astellas Pharma Inc, H2 2020
  • Overactive Bladder - Pipeline by Bayer AG, H2 2020
  • Overactive Bladder - Pipeline by DelNova Inc, H2 2020
  • Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H2 2020
  • Overactive Bladder - Pipeline by Dong-A ST Co Ltd, H2 2020
  • Overactive Bladder - Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2020
  • Overactive Bladder - Pipeline by Evestra Inc, H2 2020
  • Overactive Bladder - Pipeline by Exxel Pharma Inc, H2 2020
  • Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H2 2020
  • Overactive Bladder - Dormant Projects, H2 2020
  • Overactive Bladder - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Overactive Bladder, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12609IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2020, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 8, 3, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Overactive Bladder - Overview
  • Overactive Bladder - Therapeutics Development
  • Overactive Bladder - Therapeutics Assessment
  • Overactive Bladder - Companies Involved in Therapeutics Development
  • Overactive Bladder - Drug Profiles
  • Overactive Bladder - Dormant Projects
  • Overactive Bladder - Discontinued Products
  • Overactive Bladder - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.